Literature DB >> 15870827

The difference between observed and expected prevalence of MCAD deficiency in The Netherlands: a genetic epidemiological study.

Terry G J Derks1, Marinus Duran, Hans R Waterham, Dirk-Jan Reijngoud, Leo P Ten Kate, G Peter A Smit.   

Abstract

Medium chain acyl coenzyme A dehydrogenase (MCAD) deficiency is assumed to be the most common inherited disorder of mitochondrial fatty acid oxidation. Few reports mention the difference between the expected and observed prevalence of MCAD deficiency on the basis of the carrier frequency in the population. We performed a population-wide retrospective analysis of all known MCAD-deficient patients in The Netherlands. In this study, the observed prevalence of MCAD deficiency in The Netherlands was 1/27 400 (95% confidence interval (CI) 1/23 000-1/33 900), significantly different from the expected prevalence of 1/12 100 (95% CI 1/8450-1/18 500). The observed prevalence of MCAD deficiency showed a remarkable north-south trend within the country. From the patients in this cohort, it can be observed that underdiagnosis contributes to a larger extent to the difference between the expected and observed prevalences of MCAD deficiency in our country, than reduced penetrance. We determined estimates of the segregation proportion in a cohort of 73 families under the assumption of complete ascertainment (p(LM) = 0.41, 95% CI 0.31-0.51) and single ascertainment (p(D) = 0.28, 95% CI 0.19-0.37). With the expectation-maximization algorithm, a third estimate was obtained (p(EM) = 0.28, 95% CI 0.20-0.37). The agreement between the latter two estimates supports incomplete selection and the segregation proportions were in agreement with normal mendelian autosomal recessive inheritance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15870827     DOI: 10.1038/sj.ejhg.5201428

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  11 in total

Review 1.  The clinical manifestation of MCAD deficiency: challenges towards adulthood in the screened population.

Authors:  Ulrich A Schatz; Regina Ensenauer
Journal:  J Inherit Metab Dis       Date:  2010-06-08       Impact factor: 4.982

2.  Recurrent exercise-induced rhabdomyolysis.

Authors:  Fady Hannah-Shmouni; Kevin McLeod; Sandra Sirrs
Journal:  CMAJ       Date:  2012-02-06       Impact factor: 8.262

3.  Neonatal screening for profound biotinidase deficiency in the Netherlands: consequences and considerations.

Authors:  Rachel C Wiltink; Michelle E Kruijshaar; Rick van Minkelen; Willem Onkenhout; Frans W Verheijen; Evelien A Kemper; Francjan J van Spronsen; Ans T van der Ploeg; Klary E Niezen-Koning; Jasper J Saris; Monique Williams
Journal:  Eur J Hum Genet       Date:  2016-06-22       Impact factor: 4.246

4.  Safe and unsafe duration of fasting for children with MCAD deficiency.

Authors:  Terry G J Derks; Francjan J van Spronsen; Jan Peter Rake; Christian S van der Hilst; Mark M Span; G Peter A Smit
Journal:  Eur J Pediatr       Date:  2006-06-21       Impact factor: 3.183

5.  Medium-Chain Acyl-CoA Dehydrogenase Deficiency: Evaluation of Genotype-Phenotype Correlation in Patients Detected by Newborn Screening.

Authors:  Gwendolyn Gramer; Gisela Haege; Junmin Fang-Hoffmann; Georg F Hoffmann; Claus R Bartram; Katrin Hinderhofer; Peter Burgard; Martin Lindner
Journal:  JIMD Rep       Date:  2015-05-05

Review 6.  Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: a global perspective.

Authors:  William J Rhead
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

7.  Neonatal screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in The Netherlands: the importance of enzyme analysis to ascertain true MCAD deficiency.

Authors:  T G J Derks; T S Boer; A van Assen; T Bos; J Ruiter; H R Waterham; K E Niezen-Koning; R J A Wanders; J M M Rondeel; J G Loeber; L P Ten Kate; G P A Smit; D-J Reijngoud
Journal:  J Inherit Metab Dis       Date:  2008-01-14       Impact factor: 4.982

8.  Risk stratification by residual enzyme activity after newborn screening for medium-chain acyl-CoA dehyrogenase deficiency: data from a cohort study.

Authors:  Catharina M L Touw; G Peter A Smit; Maaike de Vries; Johannis B C de Klerk; Annet M Bosch; Gepke Visser; Margot F Mulder; M Estela Rubio-Gozalbo; Bert Elvers; Klary E Niezen-Koning; Ronald J A Wanders; Hans R Waterham; Dirk-Jan Reijngoud; Terry G J Derks
Journal:  Orphanet J Rare Dis       Date:  2012-05-25       Impact factor: 4.123

9.  Newborn screening for medium chain acyl-CoA dehydrogenase deficiency in England: prevalence, predictive value and test validity based on 1.5 million screened babies.

Authors:  Juliet Oerton; Javaria M Khalid; Guy Besley; R Neil Dalton; Melanie Downing; Anne Green; Mick Henderson; Steve Krywawych; James Leonard; Brage S Andresen; Carol Dezateux
Journal:  J Med Screen       Date:  2011-12-13       Impact factor: 2.136

10.  Medium-chain acyl-CoA deficiency: outlines from newborn screening, in silico predictions, and molecular studies.

Authors:  Serena Catarzi; Anna Caciotti; Janita Thusberg; Rodolfo Tonin; Sabrina Malvagia; Giancarlo la Marca; Elisabetta Pasquini; Catia Cavicchi; Lorenzo Ferri; Maria A Donati; Federico Baronio; Renzo Guerrini; Sean D Mooney; Amelia Morrone
Journal:  ScientificWorldJournal       Date:  2013-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.